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Background: HOX genes are a family of developmental genes that are expressed neither in the developing
forebrain nor in the normal brain. Aberrant expression of a HOX-gene dominated stem-cell signature in glioblastoma
has been linked with increased resistance to chemo-radiotherapy and sustained proliferation of glioma initiating cells.
Here we describe the epigenetic and genetic alterations and their interactions associated with the expression of this
signature in glioblastoma.
Results: We observe prominent hypermethylation of the HOXA locus 7p15.2 in glioblastoma in contrast to non-tumoral
brain. Hypermethylation is associated with a gain of chromosome 7, a hallmark of glioblastoma, and may compensate
for tumor-driven enhanced gene dosage as a rescue mechanism by preventing undue gene expression. We identify
the CpG island of the HOXA10 alternative promoter that appears to escape hypermethylation in the HOX-high
glioblastoma. An additive effect of gene copy gain at 7p15.2 and DNA methylation at key regulatory CpGs in
HOXA10 is significantly associated with HOX-signature expression. Additionally, we show concordance between
methylation status and presence of active or inactive chromatin marks in glioblastoma-derived spheres that are
HOX-high or HOX-low, respectively.
Conclusions: Based on these findings, we propose co-evolution and interaction between gene copy gain, associated
with a gain of chromosome 7, and additional epigenetic alterations as key mechanisms triggering a coordinated, but
inappropriate, HOX transcriptional program in glioblastoma.Background
Glioblastoma (GBM) is an aggressive brain tumor with a
median survival of only 15 months. Despite remarkable
efforts targeting prominent pathogenetic biological fea-
tures of GBM, efficacy of novel drugs has been disap-
pointing and significant gains in overall survival have
not been made since the introduction of combined
radio-chemotherapy comprising TMZ [1]. GBM are no-
torious for their treatment resistance. This has been* Correspondence: monika.hegi@chuv.ch
1Neurosurgery, Lausanne University Hospital, Lausanne 1011, Switzerland
2Neuroscience Research Center, Lausanne University Hospital, Lausanne 1011,
Switzerland
Full list of author information is available at the end of the article
© 2015 Kurscheid et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.attributed to the deregulation of major tumor suppress-
ing and oncogenic pathways [2], tumor heterogeneity
[3], and exhibition of stem cell-like properties by so
called tumor stem cells, or glioma initiating cells (GICs)
[4]. GICs represent a subpopulation(s) of tumor cells
and are believed to, first, give rise to tumor progeny due
to their self-renewing capacities, and second, resist
radio- and chemotherapy [5,6].
In line with the notion of GICs’ contribution to treatment
resistance, we earlier reported a self-renewal-related,
HOX-dominated gene expression signature in GBM as-
sociated with significantly worse outcome in patients
homogenously treated in a clinical trial with combinedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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temozolomide. This association was independent of the
predictive effect of MGMT methylation or age [7]. The
abnormal expression of a HOX gene signature has been
confirmed recently in GICs, where it has been func-
tionally associated with their glioma initiating potential
[8]. The importance of HOX gene expression for glio-
magenesis and treatment resistance to temozolomide
has been emphasized in several studies [8-12]. In 2006,
Krivtsov and colleagues first described the inappropri-
ate expression of a HOX gene signature in acute mye-
loid leukemia (AML) [13]. The authors showed in an
elegant experimental mouse model that acquisition of
this stem cell related HOX gene signature was associ-
ated with MLL-A9 fusion gene-induced leukemogenesis
from committed progenitors of the granulocyte lineage,
demonstrating for the first time that acquisition of
stem cell properties in committed progenitor cells can
lead to tumorigenesis.
HOX genes are a highly conserved family of genes en-
coding homeodomain transcription factors that provide
anterior and posterior axial coordinates to vertebrate
embryos during development [14]. In mammals, there
are four paralogous HOX gene clusters organized on dif-
ferent chromosomes (CHRs). These gene clusters repre-
sent loci with extremely high gene density. In humans
they are located on CHR7 (HOXA), CHR17 (HOXB),
CHR12 (HOXC), and CHR2 (HOXD). The spatial
organization of HOX genes is reflected in a 5′-posterior
to 3′-anterior expression along the embryonal axes,
termed spatial colinearity. Hence, expression of HOXA9-
13 is predominantly found in sites of the extremities,
while HOXA1-2 expression has been confirmed in, for
example, the hindbrain. Although HOX genes are in-
volved in the development of the hindbrain, other non-
HOX homeobox genes regulate the development of the
mid- and forebrain [15]. The forebrain comprises the
ventricular and the subventricular zone, which harbors
neural stem cells even in the adult brain, and has been
proposed as origin of gliomas in the adult. Although this
remains debated, mouse models have provided func-
tional support [16].
Given that HOX genes are neither implicated in the
developmental program of the brain nor expressed in
the region of the adult brain that is thought to give rise
to gliomas, we speculate that the HOX-signature is ac-
quired during gliomagenesis, contributing stem cell
properties. However, the mechanisms underlying the ob-
served aberrant activation of HOX genes in GBM remain
elusive. It has been proposed that the PI3K-pathway may
be an important upstream regulator of HOXA9 expres-
sion that is part of the HOX-signature [10]. A more
recent report considered the involvement of MLL
(KMT2A) in at least a subset of HOX-high expressingGBM. However, given the limited correlation reported,
additional driver mechanisms triggering inappropriate
HOX gene expression need to be considered [8]. Previ-
ous works have described a remarkable correlation of
gene expression levels with gene dosage modulated by
pathogenic copy number changes in cancer [17]. Most
prominent among the HOX expression signature genes
are HOXA genes, as corroborated by other labs [7,8,10].
The HOXA locus is located on CHR7 (7p15.2) that is af-
fected by a copy number gain in up to 80% of GBM
[18]. Most interestingly, gain of CHR7 has been pro-
posed recently as the evolutionary first driver event in
the development of primary GBM together with loss of
one copy of CHR10 [19]. CHR7 harbors a number of
potential driver genes, among many passengers that
through CHR7 gain associated overexpression may
drive/contribute to gliomagenesis. Of these, Ozawa et al.
proposed PDGF as a driver gene for primary GBM,
based on computational and experimental consider-
ations. Previously we reported a low, but significant cor-
relation between gene copy number of the HOXA
cluster and expression of the HOX-signature [7]. How-
ever, only 42% of this patient cohort was found to be
HOX-high. We therefore hypothesized that additional
regulatory mechanisms are required to explain the ab-
normal expression of HOXA genes, with downstream ef-
fects on other HOX-signature genes. Here we present a
model explaining the aberrant expression of the HOX-
signature in GBM integrating multidimensional molecu-
lar data, comprising gene expression, gene copy number,
and DNA methylation.
Results
Correlation between DNA methylation and gene expression
in clinical GBM samples
During gliomagenesis extensive epigenetic remodeling
takes place, including global DNA hypomethylation and
focused hypermethylation of promoter CpG-islands
(CGIs) frequently silencing tumor suppressor genes.
Recurrent gain of additional copies of CHR7 in GBM,
often referred to as trisomy 7 in the literature, likely af-
fects the HOXA locus that dominates the HOX-
signature. The ‘HOX-signature’ refers to the signature
identified previously [7], and comprises 21 genes cov-
ered by 22 probes of the HG-133Plus2.0 GeneChip
(Additional file 1: Table S1). We hypothesized that epi-
genetic silencing mediated by methylation of CpGs in
CGI-promoters of HOX-signature genes may compen-
sate for tumor driven enhanced gene dosage as a rescue
mechanism that could at least partially explain the dif-
ferences in expression. In order to test this hypothesis
we analyzed DNA methylation profiles of 59 GBM of the
NCH_EORTC cohort obtained on the Illumina Infinium
HumanMethylation450 BeadChip platform (450k). Indeed
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across the HOXA locus on CHR7 (27,130,000 to
27,250,000; hg19 UCSC), when comparing GBM to
non-tumoral brain (n = 4), with a generalized hyperme-
thylation in the GBM samples as measured at 504 450k
probes spanning the locus (P <0.001, two-sided t-test;
Additional file 1: Figures S1 and S2). DNA methylation
of the HOXA locus was significantly associated with
gain of CHR7 (P <0.001, two-sided t-test), which may
indicate compensation for increased gene dosage. In
order to identify regulatory methylation patterns rele-
vant for the expression of the whole HOX-signature
the 400 probes annotated in CGIs of the 21 HOX-
signature genes were subjected to principle componentA
B
C
Figure 1 Cross-correlation of HOX-signature gene expression and DN
visualizes the correlation between top 100 450k probes measuring DNA m
HOXA, and HOXC loci (x-axis, see Additional file 1: Table S1 for detailed probe
22 Affymetrix HG-133Plus2.0 probes (y-axis) in the NCH_EORTC GBM cohort. T
The chromosomal locations of the HOX-signature genes are color-coded. (B)
HOX-signature genes of the NCH_EORTC dataset in A. The plot in (C) displays
from TCGA using the same set of Infinium 450k probes and a total of 53 Agile
file 1: Figure S3 for the corresponding heatmap). Circles highlight probes, whi
methylation at measured CpG probes and the probes measuring expression o
Table S2 for list of Illumina Infinium 450k probes.analysis. The top 100 CpG probes were selected based
on their ranked cumulative contribution to the inertia
of the DNA methylation table, hence representing the
dominant contributors to the overall variability of the
observed DNA methylation. The top 100 probes were
predominantly located in the promoter CGIs of HOXA
genes on CHR7, followed by HOXD genes on CHR2,
HOXC genes on CHR12, and PROMININ1 on CHR4
(Figure 1A and Additional file 2: Table S2, which con-
tains mean correlation, P and q-values, and functional
annotation for all 100 selected Infinium 450k probes
for NCH_EORTC and TCGA data). The correlation be-
tween methylation of these CpGs and expression of
each member of the HOX-signature was calculated.0.8
0.4
0.0
0.4
0.8
A methylation of top 100 associated CpGs. (A) The heatmap
ethylation of CpGs located in CpG islands of the HOXD, PROMININ1,
information) and the expression of 21 HOX-signature genes measured by
he probes on both axes are ordered according to chromosomal location.
Mean correlation between each selected CpG and expression of the
the mean correlation of the validation set comprising 106 GBM samples
nt probes measuring expression of HOX-signature genes (see Additional
ch showed a statistically significant mean correlation between DNA
f HOX-signature genes (q-values, FDR < =0.1). See also Additional file 2:
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sualizes the pattern of negative and positive correlation
between DNA methylation and gene expression in the
NCH_EORTC dataset. The strongest mean negative
correlation (<= −0.28, (−0.28; 0.4)) between expression
of HOX-signature genes and methylation was observed
for a CpG probe located in the CGI associated with the
alternative transcription start site of HOXA10 (probe
ID cg05092861 in UCSC CpG Island CHR7: 27219309–
27219750, FDR <0.10) (Figure 1B, Additional file 2:
Table S2). An adjacent CpG showed a similar correl-
ation (cg01078824; −0.21, FDR <0.10; Additional file 2:
Table S2).
Determination of the correlation signature in an
independent GBM dataset
Likewise we calculated the correlation matrix between
DNA methylation and gene expression in an independ-
ent dataset of 106 GBM from The Cancer Genome
Atlas (TCGA; Additional file 1: Table S4; mean correl-
ation Figure 1C) visualized in a heatmap in Additional
file 1: Figure S3. The similarity of the structure of the
correlation matrices was remarkable for these two in-
dependent GBM datasets, with an RV-coefficient of
0.84 (simulated P value <0.001 (9,999 permutations),
Additional file 1: Figures S3 and S4). Of note, while
DNA methylation data was also generated on the 450k
platform (used as the common dimension), the expression
data originated from different platforms. In the GBM
TCGA Agilent data the HOX-signature genes are covered
with 53 probes (Additional file 1: Table S5), with probes
missing for the ncRNA genesMIR10B and HOTAIRM1.
In order to evaluate the relevance of our findings in
the context of the whole CHR7, we tested whether the
apparent local enrichment of negative correlation be-
tween HOXA gene expression and DNA methylation
at the HOXA locus was statistically significant. We
determined the negative correlations between 711
RefSeq annotated CHR7 genes and their respective
Illumina Infinium 450k probes and plotted the values
according to genomic location of the genes (Additional file
1: Figure S5A). Gene set enrichment analysis (GSEA) re-
vealed that the 10 HOXA genes were significantly enriched
when testing their positions in the ranked list of the ob-
served correlation coefficients of the 711 CHR7 genes as
visualized in Additional file 1: Figure S5B (P value <0.001,
Additional file 1: Table S3). A similar result was obtained
for the TCGA dataset (P value <0.001; Additional file 1:
Figure S5C; Table S3).
The relationship DNA methylation/gene expression
depends on CpG location
Next we were interested to evaluate the relationship of the
mean correlation methylation/HOX-signature expression(Figure 1B and C) and the structural location of the re-
spective CpGs using the Illumina annotation of the 450k
probes (1st Exon, 3′UTR, 5′UTR, gene body, transcrip-
tion start site (TSS) 1,500, TSS200). We observed that
negative correlations between DNA methylation and the
HOX-signature expression are primarily found for probes
which are located either in the 1st exon of a gene, or
within 200 bp of TSS, in line with canonical effects of
promoter-CGI methylation on gene expression, while
positive mean DNA methylation/gene expression correla-
tions were found for probes located in the 3′UTR, 5′UTR,
gene body and within 1,500 bp of TSS. This observation
was consistent between the NCH_EORTC and the TCGA
dataset (Additional file 1: Figure S6A and B, P value <0.01
and P value <0.05, one-way ANOVA).
DNA methylation at HOXA10 promoter CGI is lower in
HOX-high than HOX-low GBM
The 59 GBM (NCH_EORTC) were classified into HOX-
high (n = 25) or low (n = 34) based on iterative k-means
clustering of the 22 Affymetrix probesets (Additional file
1: Figures S7 and S8). The average expression of the
HOX-signature in the HOX-low group is not signifi-
cantly different from respective measures in non-
tumoral brain samples (P value = 0.9, all Welch’s Two-
sample t-test) (Additional file 1: Figure S9A). In contrast,
the higher mean expression levels of the HOX-signature
in HOX-high samples are significantly different to both
HOX-low (P value <0.01) and non-tumoral brain sam-
ples (P value <0.01). We observed significant differences
in the degree of DNA methylation measured for probe
cg05092861 between HOX-low and HOX-high samples,
with a higher level of DNA methylation in HOX-low
samples (P value <0.001). Both were different from non-
tumoral brain (n = 4), which showed the lowest methyla-
tion levels (P value <0.001), although no expression is
detected, while highest levels of DNA methylation were
measured in HOX-low samples (non-tumoral brain <
HOX-high < HOX-low, Additional file 1: Figure S9B).
Similar differences were observed for the adjacent Infi-
nium 450k probe cg01078824.
Correlation between expression and gene copy number
In order to investigate our hypothesis that gene dosage
may contribute to the aberrant expression of the HOX-
signature, we first tested the overall relationship between
gene dosage and gene expression in our GBM dataset
(NCH_EORTC). At the resolution of chromosomal arms
that averages out regulatory factors affecting individual
transcript levels, expression of the genes located on that
arm and corresponding DNA copy number are strongly
correlated (median Pearson correlation coefficient 0.73,
standard deviation 0.18). The gene dosage effect on ex-
pression is particularly striking for gain of CHR7 and loss
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Figure 2 for the whole NCH-EORTC cohort (Figure 2A
and B), or an individual GBM samples (Figure 2C and D).
Gene dosage and DNA methylation impact HOX-signature
expression
Next we tested the association between copy number alter-
ations (CNA) at cytoband 7p15.2 that harbors the HOXA
locus, methylation at the selected CpG (cg05098261) in the
alternative promoter of HOXA10, and mean HOX-
signature expression levels using an explanatory linear
model. The M-values of the probe cg05092861 and the re-
spective CNA values for cytoband 7p15.2 were introduced
as independent variables, while the mean HOX-signature
expression (based on scaled and centered gene expression)
was the dependent variable. We observed a significant
additive effect between CNA 7p15.2 and methylation at
the selected probe in the alternative promoter of HOXA10
as illustrated in Figure 3A. This model explains 32% of the
variance of the HOX-signature expression levels (Table 1 -
‘Model 1’). The result supports the hypothesis that DNAFigure 2 Correlation of gene expression and gene dosage across the
the NCH-EORTC cohort are shown in fine resolution. (A) Gene expression is p
and interpolated. Every row is a probeset, and probesets are sorted by their g
sorted by their genomic order. In both A and B, the samples (columns) are so
expression and aCGH values are shown. (D) For the same sample as in (C), th
median relative expression of all probesets on the same chromosomal arm. O
are shown.methylation - at least in part - acts as an attenuating factor
in samples with increased CNA at 7p15.2 in a manner that
the effect of increased gene dosage on expression may be
countered by the inhibitory effect of DNA methylation of
HOXA10 in GBM. Similar results were also observed in
the TCGA subset of 103 GBM (for 3 of the 106 TCGA
GBM the SNP6 CNA data were not available) as visualized
in Figure 3B and summarized in Table 1. The model for
the TCGA data explains 29% of the observed variance in
HOX-signature expression (Table 1 - ‘Model 1’). Similar
additive effects were observed for the adjacent CpG
(cg01078824, Table 1 - ‘Model 2’).
Given the apparent central role of HOXA10 in the
HOX-signature, X/Y plots for both series of GBM,
stratified by CHR7 status, illustrate the correlation be-
tween HOXA10 expression alone (Affymetrix probe
214651_s_at) and methylation at the above identified 2
top CpGs (cg05092861, cg01078824) in the promoter of
the putative non-coding alternative HOXA10 transcript
(NR_037939.1) and in addition at two CpGs (cg18243072,
TSS200; cg14625175, exon1) located in the CGI of theGBM genome. Overall expression and aCGH in 64 GBM samples of
lotted relative to non-tumoral brain samples. Values were smoothened
enomic order. (B) aCGH data: Every row is a marker, and markers are
rted according to standard deviation in B. (C) For a single sample, the
e median of all markers on every chromosome arm is plotted against the
nly chromosome arms for which there are probesets and aCGH markers
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Figure 3 HOX-signature expression levels are partially explained by DNA methylation and chr7p15.2 CNA. The linear model in (A)
visualizes the relationship between DNA methylation of the probe cg05092861 (M-values) and CNA at the cytoband chr7p15.2 (log2 fold-change
(FC) over normal reference sample), and its association with mean HOX-signature expression levels of the 59 NCH_EORTC GBM samples. The
projected plane represents the predicted response, and illustrates that mean HOX-signature levels are highest for samples, which have an increase
in CNA and decrease in DNA methylation. As additional information, the copy number status calls (based on segmented information from BAC
CGH data) of all samples are illustrated by circles (normal CHR7) and triangles (CHR7 gain). See Additional file 1: Figures S7 and S8 for the HOX
signature based classification of samples into HOX-high and -low. Analogue to the model used for the NCH_EORTC data, (B) illustrates the linear
model for the 103 TCGA GBM showing the combinatorial effect of CNA increase and DNA methylation decrease on the increase of mean HOX-
signature expression levels. CHR7 copy number status of individual samples is illustrated by circles (normal) and triangles (gain). Additional file 1:
Figure S11 illustrates the organization of TCGA samples into HOX-high and -low groups.
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script (NM_018951.3) (Figure 4B and C). In our dataset
(NCH_EORTC) a significant negative correlation between
expression and methylation was associated with CpG
methylation in both regions for HOXA10 expression in
GBM with CHR7 gain (Spearman’s correlation P <0.05,
Figure 4B and C). In contrast, no significant correlation
was observed in GBM with normal CHR7 status (Figure 4B
and C). Taken together, the findings for the HOX-signature
gene HOXA10 are in accordance with the model presented
in Figure 3. Similar results were obtained for the TCGA
dataset (Additional file 1: Figure S10B and C). The Spear-
man’s correlation coefficients for CpGs located in the two
HOXA10 promoters and HOXA10 expression are available
in Additional file 1: Table S6 for both datasets, stratified by
CHR7 status. Additional file 1: Table S7 comprises the cor-
relation coefficients for the top 100 CpGs and mean ex-
pression of the whole HOX-signature, stratified by CHR7
status for both NCH_EORTC and TCGA GBM.Transcriptome at the HOXA locus in GBM derived sphere
(GS) lines
We sought to extend our findings to four GBM-derived
sphere lines (GS lines) that retain GBM-relevant stem-
cell properties and provide a better model of GBM than
regular cell lines. Aligned read pile-ups derived from di-
rected RNA-Seq data shown in Figure 5 illustrate the
presence of both sense and anti-sense transcripts in the
HOXA locus in three GS lines (LN-2207GS, LN-2669GS,
LN-2683GS, thus designated as HOX-high models). In
contrast, RNA-Seq reads generated from the HOX-low
GS line LN-2540GS and human brain tissue (Ensembl
Illumina Human BodyMap 2.0) show only very few and
no aligned reads across the HOXA locus, respectively.
These data confirm that the expression of transcripts
from the HOXA locus in HOX-high GS lines is abnor-
mal when compared to adult ‘normal’ brain. In the three
HOX-high GS lines, the visualization of read alignments
show that the majority of fragments originated from
Table 1 Coefficients of linear models for HOX-signature expression in GBM datasets
Coefficients Estimate Std. Errora t valueb Pr (>|t|)c R2d VIFe
NCH_EORTC (Model 1) 0.318
(Intercept) −0.793 0.166 −4.791 1.26e-05
cg05092861 −0.453 0.110 −4.137 0.0001 1.001
CNA chr7p15.2 (BAC) 1.804 0.554 3.257 0.0019 1.001
NCH_EORTC (Model 2) 0.215
(Intercept) −0.204 0.168 −1.212 0.231
cg01078824 −0.311 0.113 −2.754 0.008 1.002
CNA chr7p15.2 (BAC) 1.822 0.594 3.066 0.003 1.002
TCGA (Model 1) 0.289
(Intercept) −0.612 0.105 −5.822 7.07e-08
cg05092861 −0.372 0.067 −5.542 2.44e-07 1.000
CNA chr7p15.2 (SNP6) 0.664 0.184 3.608 0.000 1.000
TCGA (Model 2) 0.254
(Intercept) −0.158 0.088 −1.785 0.077
cg01078824 −0.356 0.071 −4.962 2.87e-06 1.023
CNA chr7p15.2 (SNP6) 0.799 0.191 4.186 6.13e-05 1.023
aStandard error.
bt-statistics.
cTwo-sided P values of t-statistic.
dR-squared provides information about the variance explained by the model.
eVariance inflated factor (VIF), provides information about multi-collinearity of the model variables.
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HOXA9 exons. We then used the RNA-Seq data to per-
form reference annotation based transcript assembly
using cufflinks. This mapped transcript fragments of the
three HOX-high GS lines to 12 of the 15 canonical
HOXA sense and anti-sense transcripts. Additionally,
using transcriptome re-assembly we found that the map-
ping of some of the transcript fragments suggests that a
read-through transcript may be present, possibly consist-
ing of exons of HOXA10, miR-196b, HOXA9, and the
putative protein-coding RNA RP1-170O19.20. The pres-
ence of the AFFY-probes 214651_s_at and 209905_at in
the HOX-signature that have been annotated as long
non-coding RNA gene HOXA10-HOXA9 lend some sup-
port to these findings. A model of this putative read-
through transcript, based on the cufflinks reconstruction
of the transcriptome of the GS lines, is visualized in the
HOXA locus displayed in Figure 5. A Sashimi plot of the
HOXA10-9 locus (Additional file 1: Figure S12) illustrates
the presence of transcript fragments, which span the
exon/exon junctions of HOXA9, HOXA10, miR-196b, and
RP1-170O19.20. However, further studies are warranted.
Histone marks and promoter methylation at the HOXA10/
9 promoters
One important regulatory mechanism of transcription is
the conformational state of chromatin, as mediated
through various post-translational histone modifications.The observation that HOXA genes are actively tran-
scribed in a subset of GBM and in three of our four GS
lines indicates that the chromatin is in a permissive
state. We tested this assumption by performing
chromatin-immunoprecipitation (ChIP) in the four GS
lines for three different histone marks: H3K4me3 - mark
for active or poised promoters; H3K36me3 - indicative
of transcriptional elongation; and H3K27me3 - a repres-
sive mark, followed by qPCR at the promoters of
HOXA10 and HOXA9 (Figure 6A and B). ChIP-qPCR re-
vealed a predominant signal for H3K4me3 and presence
of H3K36me3 in the HOX-high GS lines (LN-2207GS,
LN-2669GS, LN-2683GS) in the HOXA10 promoter,
while they were absent in the HOX-low GS line LN-
2540GS. In contrast, the predominant mark detected in
the HOXA9 promoter was H3K36me3, while the other
marks were absent. In addition, we determined the
methylation status using methylation-specific (MS) clone
sequencing of the CpG island of the HOXA10 promoter
(CHR7:27212417–27214396) in three GS lines (2 HOX-
high and 1 HOX-low) and their respective original
GBM. The methylation pattern in the GS lines was
highly similar to the original primary tumors from
which they were isolated, excluding an in vitro artifact
(Figure 6C and D). The HOXA10 promoter was
unmethylated in the two HOX-high GS lines LN-
2207GS and LN-2669GS and their respective original
GBM, and fully methylated in the HOX-low GS line
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Figure 4 Correlation of HOXA10 expression and DNA methylation at the canonical and alternative promoter in 59 NCH_EORTC samples,
stratified by CHR7 status. The genomic organization of the HOXA10 region on CHR7 is illustrated in (A) based on RefSeq annotation, retrieved from
Ensembl using reference genome hg19/GRCh37. In addition the location of Infinium 450k probes are shown by grey bars at the bottom of the panel.
Red bars highlight the location of the CpGs used for the plots in (B) and (C). In (B) four X/Y plots show the correlation between DNA methylation of
two CpGs located in the canonical HOXA10 promoter (Region 1) and expression of the Affymetrix probe 214651_s_at. The top row of panels (B) and
(C) show the expression and DNA methylation of samples with gain of CHR7 (n = 38). Bottom row of panels (B) and (C) show the corresponding data
from samples with normal CHR7 status (n = 21). The CHR7 status was given by normal mixture model based on the weighted mean of the segmented
copy number. Pearson’s product moment correlation coefficient (cor) and P values are shown above each plot. Black lines in the plots show the fit of
linear regression, in green local regression using lowess smoothing is shown. Figure S10 in Additional file 1 shows the correlation between gene
expression and DNA methylation for 103 TCGA samples.
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roborates our finding of strong negative correlations
between expression/methylation for 2 CpGs (cg18243072,
cg14625175) interrogated in this region on the 450k
BeadChip, as illustrated and annotated in X-Y-plots for
both NCH_EORTC (Figure 4) and TCGA samples
(Additional file 1: Figure S10). MS clone sequencing of
the HOXA9 promoter (CHR7:27205048–27205315) re-
vealed full methylation also in the HOX-high GS lines
(Figure 6E). Taken together, the marks for actively tran-
scribed chromatin are in accordance with HOXA10 ex-
pression. HOXA10 is also translated into protein as we
have shown previously for GS lines, including LN-2207GS and a series of GBM on a tissue micro array
[7]. The observed enrichment for the elongation mark
H3K36me3 at the fully methylated HOXA9 promoter
would be compatible with the presence of a putative
read-through transcript of HOXA10 and HOXA9, as
suggested by our analyses of the RNA-Seq data (Figure 5
and Additional file 1: Figure S12) and the probe anno-
tation from the HG-133Plus2.0 GeneChip.
HOX-signature associated microRNAs
To test for the potential impact of regulatory microRNAs
on the HOX-signature we analyzed the correlation be-
tween the mean expression of the HOX-signature in the
Figure 5 RNA-Seq of four glioma sphere lines and one human brain sample. Read densities at base pair resolution are shown across a 110
kB region of CHR7 (27,130,000-27,240,00) covering the human HOXA locus. Density of transcripts are presented separately for the minus (black)
and plus (gray) strand and are shown as rpm/bp. The RefSeq annotations of the HOXA genes are shown as visual reference below the histograms.
The location and structure of the putative HOXA9/10 read-through transcript is indicated in the RefSeq annotation track as a red gene model.
See Additional file 1: Figure S12 for a Sashimi plot of RNA-Seq reads which support the presence of the read-through transcript. Locations of CpG
islands (UCSC) are indicated by green bars. The gray boxes labelled A/B/D/E show the locations of amplicons used for ChIP-qPCR and
methylation-specific clone sequencing (results shown in respective panels of Figure 6).
Kurscheid et al. Genome Biology  (2015) 16:16 Page 9 of 15TCGA Agilent data subset and the expression levels of
individual microRNAs (Table 2). We found that the
top correlated microRNAs (Spearman’s rho > = 0.5, P
value <0.0001) were in fact transcribed from HOX loci
(miR-196b - HOXA, miR-10a - HOXB, miR-10b -
HOXD), known to have regulatory functions in cis
[20]. However, the expression of these microRNAs was
positively correlated, suggesting that the de-repression
of HOX genes in GBM may lead to an overall aberrant
co-expression of genes from the affected loci including
the enclosed microRNAs. This is further supported by
the observation that several long non-coding RNAs
transcribed from the HOXA (HOTAIRM1) and HOXC
loci (LOC400043, HOTAIR) and adjacent to the HOXD
locus (LOC375295), were detected as part of the HOX-
signature (Additional file 1: Table S1).Relationship of the HOX-signature and molecular GBM
subtypes
Next we sought to address how the HOX-signature was
related to three established molecular GBM classification
schemes: (1) the four GBM expression subtypes neural,
proneural, mesenchymal, and classical as proposed by
Verhaak and colleagues [21]; (2) the glioma CpG island
methylator phenotype (G-CIMP) present in a subgroup
of proneural GBM [22]; or (3) distinction of MGMT
promoter methylated vs. unmethylated that has been
shown to be highly predictive for benefit from alkylating
agent chemotherapy [23]. Expression data from 473
GBM (TCGA, level 2 Agilent) were used to classify
samples into either HOX-high (259) or low (214), based
on k-means clustering (Additional file 1: Figure S13),
and were annotated with the expression subtype
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Figure 6 Epigenetic features of the HOXA10 and HOXA9 promoters. ChIP-qPCR is shown for three different histone marks, two associated with
active transcription/open chromatin (H3K4me3, H3K36me3) and one indicative of transcriptional repression (H3K27me3), in our four glioma sphere lines
at the HOXA10 promoter (A) and the HOXA9 promoter (B). The measurements represent relative enrichment over IgG control (error bars represent SEM
in duplicate experiments). Methylation-specific clone sequencing is shown for the CpGi located in the promoter of HOXA10 in three primary GBM (C)
and respective derived glioma sphere lines (D). The HOXA10 promoter of HOX-high GBM-2207 and GBM-2669, and the corresponding GS lines (LN-
2207GS, LN-2669-GS) is unmethylated, in contrast to the HOX-low GBM-2540 and its corresponding GS line which exhibit both a highly methylated
HOXA10 promoter. (E) The CpGi located in the promoter of HOXA9 is highly methylated in all three glioma spheres lines. Gray boxes represent
methylated CpGs.
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methylation status [2,24] (Additional file 1: Figure S14).
We observed an enrichment of proneural GBM in the
HOX-high group, while the proneural G-CIMP-positive
GBM were under-represented (Additional file 1: Table
S8, P value <0.001, Pearson’s Chi-squared test). No sig-
nificant associations were found in the other three ex-
pression subtypes. No correlation was found with
expression of PDGF that has been proposed as a gain
of CHR7-associated driver gene for G-CIMP negative
GBM [19]. Finally, we confirmed our previous finding
from the NCH_EORTC dataset [7] that the MGMT-
promoter methylation frequency was not differentbetween the HOX-high and low groups (Additional file 1:
Table S9, P value >0.35, Pearson’s Chi-squared test).
Discussion
In the present study we sought to elucidate underlying
molecular mechanisms triggering the inappropriate ex-
pression of a HOX-signature. Such a HOX gene domi-
nated expression signature has been associated by
others, and us with resistance to temozolomide and con-
ferring of glioma-initiating properties [7,8,11,12].
The hypermethylation of the HOXA locus was asso-
ciated with gain of CHR7, which is reminiscent of
compensation for increased gene dosage, known from
Table 2 Correlation between microRNAs and mean HOX-
signature expression in 106 GBM samples from TCGA,
top 2 percentile positively and negatively correlated
microRNAs
Spearman’s rho P value
(two-sided)
hsa-miR-196b (HOXA locus) 0.69 <0.01
hsa-miR-10b (HOXD locus) 0.50 <0.01
hsa-miR-196a (HOXB/C locus) 0.5 <0.01
hsa-miR-148a 0.42 <0.01
hsa-miR-106b 0.35 <0.01
hsa-miR-25 0.32 <0.01
hsa-miR-496 0.31 <0.01
hcmv-miR-UL148D 0.3 <0.01
hsa-miR-337 0.29 <0.01
hsa-let-7c 0.29 <0.01
hsa-miR-130b 0.29 <0.01
hsa-miR-199a* −0.27 <0.01
hsa-miR-223 −0.27 <0.01
hsa-miR-148b −0.28 <0.01
hsa-let-7f −0.29 <0.01
hsa-miR-125a −0.29 <0.01
hsa-let-7d −0.3 <0.01
hsa-miR-98 −0.3 <0.01
hsa-let-7 g −0.33 <0.01
hsa-miR-143 −0.36 <0.01
hsa-miR-107 −0.37 <0.01
hsa-miR-145 −0.42 <0.01
Lines in bold highlight microRNAs transcribed from HOX loci.
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supported by the observation that a significant correl-
ation between DNA methylation and expression was
only observed for samples with gain of CHR7 as visual-
ized for HOXA10. The involvement of gene dosage me-
diated induction of HOX-signature expression is
compatible with the observation that HOX-high GBM
are under-represented in G-CIMP positive GBM,
which reportedly have a much lower frequency of
CHR7 gain [2]. The observed correlation between ex-
pression of the whole HOX-signature and DNA methy-
lation suggested DNA methylation patterns permissive
for expression. However, the regulatory effects leading
to coordinated expression of HOXA, C, and D genes,
and the other members of the signature, including the
stem cell marker PROM1 that are located on other
chromosomes, are not yet explained. With the excep-
tion of the developing forebrain where HOX genes are
repressed [29], the coordinated expression and silen-
cing of HOX genes is well known from embryonic de-
velopment. It involves changes of higher chromatinorganization and complex regulation implicating long-
range control mechanisms which are only partly
understood [14].
HOX genes are tightly regulated through polycomb-
repressor complex 2 (PRC2)-mediated tri-methylation of
H3K27 [30]. Investigation of GS lines suggested loss of
the repressive mark H3K27me3 and gain of the active
mark H3K4me3 in the promoter of HOXA10 protein-
coding transcript variant 1 in HOX-high GS lines, and
was associated with an unmethylated CGI. This observa-
tion is in accordance with the detection of HOXA10
protein in HOX-high GS lines, as well as in a subset of
GBM [7]. In contrast, the HOX-low GS line lacked the
active mark and displayed a methylated HOXA10 pro-
moter. Interestingly, the histone marks in the HOXA9
promoter displayed enrichment of H3K36me3 in the
HOX-high GS lines in conjunction with the fully methyl-
ated CGI suggested transcriptional elongation. This pat-
tern of histone marks would also be compatible with
presence of a HOXA10/9 read-through transcript, as
proposed by the RNA-Seq analysis and the respectively
annotated HG-133Plus2.0 probes that are part of the
HOX-signature. Little is known about the functional
relevance of the putative long non-coding RNA gene
HOXA10-HOXA9. It has been proposed as candidate for
nonsense-mediated mRNA decay (NMD) [31-33].
Non-coding RNAs, like lincRNAs and microRNAs,
can be involved in the regulation of HOX gene expres-
sion [34-36]. Our HOX-signature also includes several
lincRNAs, which are transcribed from the different HOX
loci: LOC400043 and HOTAIR from the HOXC locus,
HOTAIRM1 from the HOXA locus, and LOC375295
from the HOXD locus. For the lincRNAs HOTAIR and
HOTAIRM1 functions have been investigated. HOTAIRM1
can regulate the expression of HOXA genes through facili-
tating conformational changes to the chromatin, in prox-
imal distal manner [35-38]. An initial suspicion that
HOTAIRM1 and other ncRNAs could be directly involved
in the regulation of the HOX-signature genes was tantaliz-
ing. However, their expression pattern, and the observation
that the top three correlated microRNAs are actually tran-
scribed from the HOXA/B/C/D loci, rather suggested that
these small and long ncRNAs are more likely ‘caught in the
storm’ of a coordinated, but inappropriate HOX transcrip-
tional program.
Conclusions
In conclusion, our results suggest that the aberrant ex-
pression of the HOX-signature, which confers stem-cell
related properties and resistance to therapy, may be ac-
quired through gene copy gain associated with CHR7
gain. Hypermethylation appears to compensate for gene
copy gain at this locus in the HOX-low GBM, prevent-
ing CHR7 gain driven increase of expression, while in
Kurscheid et al. Genome Biology  (2015) 16:16 Page 12 of 15HOX-high GBM key CpGs in the HOXA locus escape
hypermethylation. Gene copy gain and methylation at
key CpGs in the promoter of HOXA10 putative non-
coding transcript variant 2 are strongly associated with
the expression of the whole HOX-signature. These find-
ings are remarkably reproducible in an independent
GBM dataset from TCGA. The observed mechanism of
escape from DNA hypermethylation may explain over-
expression of other gliomagenesis relevant proto-
oncogenes located on CHR7 and other loci affected by
tumor-related increased gene dosage. Hence, further
studies are warranted to investigate the co-evolution of
gene copy number changes and epigenetic changes, in-
cluding tumorigenesis-associated DNA methylation, to
identify tumor relevant deregulated genes. Finally, the
observation of compensatory DNA methylation at genes
with potential proto-oncogenic function should be taken
into account when considering epigenetic drugs.Methods
GBM datasets and GBM derived sphere lines
Our patient cohort of 59 GBM patients (NCH_EORTC),
for whom Affymetrix HG-133Plus2.0 gene expression
and Illumina Infinium 450k DNA methylation data were
available, has been treated within clinical trials [39,40].
Patients treated within EORTC 26981 had consented for
translational research of their tumor tissues as part of
the study protocol. All other patients gave informed con-
sent according to the protocol approved by the local eth-
ics committee (protocol F25/99) and the respective
competent Swiss federal authorities (No 1.05.01.10-48).
The study protocols conform to the World Medical
Association Declaration of Helsinki [41]. Analysis of
non-tumoral brain samples and the establishment of
the GBM derived sphere lines (GS lines) LN-2207GS,
LN-2540GS, LN-2669GS, and LN-2683GS, respective
authentication, and the description of the respective
original tumors have been published previously
[7,42,43]. Briefly, GS lines were cultured under stem
cell conditions using DMEM-F12 medium (Invitrogen,
10565–018) supplemented with human recombinant
EGF and human recombinant basic FGF (Peprotech,
AF-100-15 and 100-18B), 20 ng/mL each, and 2% B27
(Invitrogen, 17504); 50% of the medium was substituted
twice weekly.Bisulfite treatment and methylation-specific (MS) clone
sequencing, and DNA methylation profiling
DNA isolated from frozen tissues or cells was treated with
bi-sulfite, and methylation profiling was performed using
Infinium HumanMethylation450 BeadChip (Illumina). MS
clone sequencing was performed as previously described
[42]. See also Extended Experimental Procedures.RNA-Seq of glioma sphere transcriptomes and data
analysis
Total RNA isolated from GS cells was depleted from
ribosomal RNA and sequencing libraries were prepared
using TruSeq Stranded Total RNA with Ribo-Zero Gold
(Epicentre, Illumina), followed by paired-end sequencing
on Illumina Hiseq (PE 2x50 bp; NXTGNT, University of
Gent, Belgium). Details on read-alignment, transcrip-
tome reconstruction and data visualization can be found
in the Extended Experimental Procedures.
Chromatin immunoprecipitation followed by quantitative
PCR (ChIP-qPCR)
Chromatin was prepared using the MAGnify Chromatin
Immunoprecipitation System (Invitrogen), precipitated with
antibodies targeting the interrogated histone marks, and
DNA quantified using qPCR as previously described [42].
See Extended Experimental Procedures for details on the
procedure and antibodies used for immunoprecipitation.
aCGH dataset
For the NCH_EORTC samples, the Bacterial Artificial
Chromosome (BAC) aCGH data were acquired by UCSF
Humarray 2.0 and 3.0 platforms containing 2,428 BACs,
each spotted in triplicate, distributed over the human
genome with an average resolution of 1.4 Mb [18,44].
Details on data processing and analysis are presented in
the Extended Experimental Procedures.
Selection of TCGA samples included in the analysis and
data processing
We applied two criteria to select samples from TCGA
for our validation dataset: First, the gene expression
platform should have sufficient coverage of the HOX-
signature in terms of probes measuring expression levels
of all 21 genes. Second, DNA methylation should be
measured with the Illumina Infinium 450k platform, as
this provided us a common dimension necessary to as-
sess the similarity between the two datasets. Details on
the sample selection are presented in the Extended Ex-
perimental Procedures.
Data analysis
Unless otherwise stated, all data processing, analysis,
and visualization were performed in R version 3.1.0 [45].
Packages for specific data types and tasks are listed in
the relevant sections.
Processing and normalization of Illumina Infinium 450k
DNA methylation data
The methylation array data of samples was loaded into R
and processed using the BioConductor package ‘minfi’.
The detection P-values, probabilities that the target se-
quence signal was distinguishable from the background,
Kurscheid et al. Genome Biology  (2015) 16:16 Page 13 of 15were used to exclude probes with poor quality. The probes
that are unsuccessfully measured (p-detection >0.01) in
more than 1% of samples were dropped from the dataset.
The DNA methylation data from the 450k BeadChip were
preprocessed as in Genome Studio (software provided by
Illumina) and they were summarized by M-values as rec-
ommended by Du et al. [46].
Processing and normalization of Affymetrix gene
expression data
The expression intensities for all probe sets from Affymetrix
CEL-files were estimated using robust multiarray average
(RMA) with probe-level quantile normalization and the
Normalized Unscaled Standard Errors values (NUSE) were
used to assess the relative quality of arrays. The R packages
affy and affyPLM from BioConductor [47] were used to es-
tablish normalization and NUSE values.
Normalization of Agilent gene expression data
Level 1 Agilent gene expression data were downloaded
from the TCGA for 106 samples for which Infinium
450k DNA methylation data were available. The intensities
within array were normalized using Loess normalization,
followed by quantile normalization between arrays. Miss-
ing values were imputed using nearest neighbor averaging
method. In a last step, average intensities were calculated
for probes, which are present more than once.
HOX classification of samples
We used the scaled and centered gene expression data
for the 22 and 53 probes measuring levels of HOX-
signature genes in the NCH_EORTC and TCGA sam-
ples, respectively. These data were used as input for an
iterative k-means clustering procedures. Parameters were
chosen to search for the most stable cluster consisting of
two to eight groups of samples, and 10,000 iterations
were performed. The number of groups was selected
based on which number of clusters had the maximum
Calinksi-Harabasz criterion value [48], thus representing
the most stable partitioning of samples into groups/clus-
ters. The mean HOX-signature expression levels were
then calculated for the different groups and ‘high’ and
‘low’ classes were assigned based on the observed mean
population-wide expression levels (means of the HOX-
high/-low sample means).
Selection of Illumina Infinium 450k probes
Probes measuring DNA methylation of the promoters of
21 HOX signature genes were selected based on their
annotated location, resulting in a list of 400 probes. To
reduce the dimensionality of the DNA methylation data,
principle component analysis was performed and only
the 100 probes with the highest cumulative contributionretained. Further details on the procedure are presented
in the Extended Experimental Procedures.
Correlation between gene copy number and expression
Expression data and aCGH profiling were available for
64 GBM samples of the NCH_EORTC cohort. For each
of those samples, the median aCGH value and the me-
dian gene expression value (after each gene was mean
centered and divided by the standard deviation of its ex-
pression across those samples) were calculated for each
of the 39 autosomal chromosome arms. Pearson correl-
ation coefficients between the median aCGH values and
median expression values of all chromosomal arms were
calculated per sample as described [17].
Correlation between DNA methylation and expression
Pearson cross-correlation matrices were computed sep-
arately to investigate relationship between the filtered
methylation data and HOX expression signature datasets
for both NCH_EORTC and TCGA samples. A descrip-
tion of the detailed statistical procedure can be found in
the Extended Experimental Procedures.
Correlation of TCGA GBM Agilent gene and microRNA
expression data
The correlation between mean HOX-signature gene ex-
pression levels and microRNA expression levels were
calculated using Spearman’s rho statistic to estimate
rank-based measure of association, for 96 of the 106
TCGA GBM samples. The top 2 percentile positively
and negatively correlated microRNAs were selected for
further inspection.
Additive effect of CNA and DNA methylation on mean
HOX-signature expression levels
Mean HOX-signature expression level of each sample
was calculated from the scaled and centered expression
values of each probe (22 for NCH_EORTC, 53 for
TCGA). This value was then designated as the response
variable of the linear model. The DNA methylation
levels of the probe (M-values) were used as the first ex-
planatory variable, and as a second term the CNA levels
as determined by circular binary segmentation at cyto-
band chr7p15.2 were added (log2 fold-change of tumor
over diploid reference):
Mean HOX signature expressionð Þ
e
DNA methylation
selected 450k probe M ‐ value½ ð Þ þ CNA 7p15:2 logRR½ ð Þ
Data access
Gene expression profiles, DNA copy number alteration
data (array comparative genomic hybridization (aCGH))
and DNA methylation profiles have in part been
Kurscheid et al. Genome Biology  (2015) 16:16 Page 14 of 15previously published [7,24,49], and are available in the
Gene Expression Omnibus (GEO) database at [50] (ac-
cession-number: GSE7696; GSE60507; GSE60274). Due
to patient privacy concerns, the RNA-Seq data in the
form of raw sequencing data will be made available upon
request to the corresponding author, MEH. The molecu-
lar profiles of GBM from The Cancer Genome Atlas
project (TCGA) were downloaded from [2,51,52].
Additional files
Additional file 1: Figures S1 to S15, Tables S1 and S3 to S10 and
corresponding figure legends, as well as Extended Experimental
Procedures in portable document format.
Additional file 2: Table S2. Mean correlation with HOX signature
expression and P values of top 100 selected Infinium 450k probes in
NCH_EORTC and TCGA datasets.
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